Skip to content
Evigrade
ModerateAngiotensin-converting enzyme inhibitors (ACEi)×Proton pump inhibitors

Updated · Methodology

Mechanism

Enalapril is converted in the body to the active enalaprilat, with no other significant metabolism, and enalaprilat is excreted mainly by the kidneys (Renitec SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Cytochrome P450 enzymes in the liver metabolise omeprazole completely, mainly CYP2C19 and to a lesser extent CYP3A4. Omeprazole moderately inhibits CYP2C19, and its metabolites are excreted mainly in the urine (Losec SmPC, AEMPS). The enalapril documents describe neither a role for CYP2C19 nor absorption that depends on gastric acidity, and no document names this pair (Renitec and Losec SmPCs, AEMPS; Vasotec and Prilosec labels, US Food and Drug Administration, FDA). What they share are kidney warnings. Renal failure has been reported in some people taking enalapril, mainly those with severe heart failure or kidney disease. Acute tubulointerstitial nephritis, which can progress to renal failure, has been seen in people taking omeprazole (Renitec and Losec SmPCs, AEMPS).

Symptoms

The documents describe no symptoms specific to this combination. The shared concern is the kidneys. Enalapril can cause dizziness, cough and low blood pressure, including on standing. Angioedema of the face, lips, tongue or larynx can occur at any time during treatment (Renitec SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Omeprazole commonly causes headache, abdominal pain, constipation, diarrhoea, flatulence, nausea or vomiting (Losec SmPC, AEMPS). Acute tubulointerstitial nephritis with omeprazole can begin at any time during treatment and can progress to renal failure (Losec SmPC, AEMPS).

Management

The combination is not contraindicated, and the documents give no measures specific to this pair. The warnings for both drugs mention renal failure, however, so the combination requires caution (Renitec and Losec SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). In renal impairment, the starting dose of enalapril is set by creatinine clearance, and potassium and creatinine are monitored regularly (Renitec SmPC, AEMPS). In bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney, enalapril is started at low doses under close supervision, with monitoring of renal function (Renitec SmPC, AEMPS). If acute tubulointerstitial nephritis due to omeprazole is suspected, omeprazole is stopped and appropriate treatment is started promptly (Losec SmPC, AEMPS). The doses of enalapril and omeprazole are not changed because of the combination itself, as the documents describe no pharmacokinetic interaction between them (Renitec and Losec SmPCs, AEMPS; Vasotec and Prilosec labels, US Food and Drug Administration, FDA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Enalapril

Other interactions with Omeprazole